PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
P/E ratio for PainReform Ltd. (PRFX)
P/E ratio as of 2023: -1.44
According to PainReform Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.44. At the end of 2022 the company had a P/E ratio of -12.01.
P/E ratio history for PainReform Ltd. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.44 |
| 2022 | -12.01 |
| 2021 | -43.22 |
| 2020 | -310.02 |
| 2019 | -827.28 |
| 2018 | -1132.23 |
| 2017 | -44.12 |